American Society for Microbiology, Journal of Virology, 2023
DOI: 10.1128/jvi.01864-22
Full text: Download
Studies suggest that the protection against SIV/simian-human immunodeficiency virus (SHIV) acquisition afforded by the SIV/HIV V1 deletion-containing envelope immunogens, delivered by the DNA/ALVAC vaccine platform, requires multiple innate and adaptive host responses. Anti-inflammatory macrophages and tolerogenic dendritic cells (DC-10), together with CD14 + efferocytes, are consistently found to correlate with a vaccine-induced decrease in the risk of SIV/SHIV acquisition.